In the aforementioned SONIC trial, 50% of CD patients who were in clinical remission, as expressed by the CDAI (Crohn’s Disease Activity Index) score, had endoscopic and/or biochemical (CRP) active disease [138]. The gene discussed is CRP; the disease is Crohn disease.